Get the Stockscreener App
1.24
40.70%
0.3587
After Hours:
1.16
-0.08
-6.45%
Briacell Therapeutics Corp stock is traded at $1.24, with a volume of 8.15M.
It is up +40.70% in the last 24 hours and up +57.44% over the past month.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
See More
Previous Close:
$0.8813
Open:
$0.938
24h Volume:
8.15M
Relative Volume:
2.16
Market Cap:
$33.78M
Revenue:
-
Net Income/Loss:
$-6.00M
P/E Ratio:
-9.2676
EPS:
-0.1338
Net Cash Flow:
$-31.01M
1W Performance:
+81.76%
1M Performance:
+57.44%
6M Performance:
-56.64%
1Y Performance:
-80.16%
1-Day Range:
$0.887
$1.32
1-Week Range:
$0.6255
$1.32
52-Week Range:
$0.4641
$6.2994
Briacell Therapeutics Corp Stock (BCTX) Company Profile
Name
Briacell Therapeutics Corp
Sector
Industry
Phone
(604) 921-1810
Address
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER
Briacell Therapeutics Corp Stock (BCTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-22 | Initiated | H.C. Wainwright | Buy |
Briacell Therapeutics Corp Stock (BCTX) Latest News
Understanding the Risks of Investing in BriaCell Therapeutics Corp (BCTX) - Knox Daily
A closer look at BCTX’s price-to-free cash flow ratio - US Post News
BriaCell Therapeutics Corp’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - The InvestChronicle
BriaCell Therapeutics Corp [BCTX] stock Initiated by H.C. Wainwright analyst, price target now $25 - The DBT News
BriaCell Therapeutics Corp. (NASDAQ:BCTXW) Sees Significant Decline in Short Interest - Defense World
Deeper Dive: Understanding BriaCell Therapeutics Corp (BCTX) Through its Various Ratios - The Dwinnex
A new trading data show BriaCell Therapeutics Corp (BCTX) is showing positive returns. - SETE News
BriaCell Therapeutics Corp’s latest rating changes from various analysts - Knox Daily
Research Analysts Offer Predictions for BriaCell Therapeutics Corp.’s FY2024 Earnings (NASDAQ:BCTX) - Defense World
Brokers Set Expectations for BriaCell Therapeutics Corp.’s FY2024 Earnings (TSE:BCT) - Defense World
HC Wainwright Weighs in on BriaCell Therapeutics Corp.’s FY2029 Earnings (TSE:BCT) - Defense World
BriaCell Therapeutics target cut by H.C. Wainwright - Investing.com
BriaCell Therapeutics (CVE:BCT) Given New C$15.00 Price Target at HC Wainwright - Defense World
Oncolytics Biotech Inc - Baystreet.ca
BioLife Solutions, Inc. (NASDAQ:BLFS) CRO Garrie Richardson Sells 3,070 Shares - Defense World
Ra capital executives buy Bicara Therapeutics shares for $32.99m - Investing.com India
BriaCell Therapeutics Corp. - Baystreet.ca
BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients - GlobeNewswire
BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients - StockTitan
Cantor Fitzgerald Reiterates “Overweight” Rating for BridgeBio Pharma (NASDAQ:BBIO) - Defense World
Bridgeline Digital CEO purchases $2,600 in company stock By Investing.com - Investing.com UK
Goodwin Advises Bicara’s $362 Million Upsized Initial Public Offering - Goodwin Procter
Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity - Pharmaceutical Technology
Market Update: BriaCell Therapeutics Corp (BCTX) Sees Negative Movement, Closing at 0.49 - The Dwinnex
Holdings of BriaCell Therapeutics Corp (BCTX) are aligned with the stars - SETE News
1,905 Shares in BridgeBio Pharma, Inc. (NASDAQ:BBIO) Bought by Headlands Technologies LLC - Defense World
Bicara Therapeutics raises $362 million in Nasdaq debut - The Pharma Letter
The Potential Rise in the Price of BriaCell Therapeutics Corp (BCTX) following insiders activity - Knox Daily
Bicara Therapeutics Announces Closing of $362 Million - GlobeNewswire
How does BCTX’s price to cash per share ratio compare in the market? - US Post News
Brixmor price target raised to $28 from $27 at Evercore ISI - TipRanks
The Future of BriaCell Therapeutics Corp: Analyzing BCTX - The InvestChronicle
The Potential Rise in the Price of Brixmor Property Group Inc (BRX) following insiders activity - Knox Daily
Arizona State Retirement System Grows Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World
Brixmor stock hits 52-week high at $27.73 amid robust growth - Investing.com
BriaCell Therapeutics Corp. (NASDAQ:BCTXW) Sees Significant Increase in Short Interest - Defense World
Bicara Therapeutics Opens at $26.25 , Upsized IPO Priced at $18 By Investing.com - Investing.com Canada
Bicara Therapeutics Rises 39% in Debut on Nasdaq - MarketWatch
3 Biotech IPOs, $703M Raised for Clinical Trials in Cancer, Immunology & Endocrine Disorders - MedCity News
TPG-backed Bicara Therapeutics shares surge 46% in stellar market debut - MSN
BriaCell raises $8.5M following positive results for its experimental cancer therapy - The Business Journals
Bicara Therapeutics Opens at $26.25 , Upsized IPO Priced at $18 - Investing.com India
Financial Health Report: BriaCell Therapeutics Corp (BCTX)’s Ratios Tell a Tale - The Dwinnex
Biotech raises $315 million in IPO, surpassing $250M target - The Business Journals
Bicara Leads Trio of US Biotech IPOs Raising $703 Million - Bloomberg
Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering - ForexTV.com
Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering - StockTitan
BriaCell Completes $8.5 Million Share Offering - TipRanks
BriaCell Therapeutics Announces Closing of $8.5 Million Offering - GlobeNewswire
BriaCell Therapeutics Announces Closing of $8.5 Million Offering - StockTitan
H.C. Wainwright maintains Buy rating on BriaCell shares with steady price target - Investing.com
Briacell Therapeutics Corp Stock (BCTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):